StreetInsider.com News Articles

Jaguar Health MVID trial moves to extension phase ahead of 2027 NDA

Thu, 10 Sep 2026 09:01:45 -0400

Jaguar Health, Inc. (NASDAQ: JAGX) subsidiary Napo Pharmaceuticals announced that all randomized pediatric patients in its pivotal crossover clinical trial of crofelemer for microvillus inclusion disease (MVID) with intestinal failure have entered a single-blind extension phase, according to a press release dated September 10, 2026.

The extension phase will have patients receive blinded doses of crofelemer powder for oral solution as adjunctive therapy to parenteral support. The trial is running at multiple centers in the United States, the European Union, and the United Arab Emirates. Napo expects the data to support a New Drug Application filing for the MVID indication in

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failu

Thu, 10 Sep 2026 09:00:00 -0400

Continuation of treatment with blinded doses of crofelemer in the extension phase of the trial will support company's plans to file an NDA in mid-2027 for MVID, an ultrarare pediatric disease

SAN FRANCISCO, CA / ACCESS Newswire / September 10, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that all randomized pediatric MVID patients in Napo's pivotal crossover clinical trial have entered the single-blind extension phase to receive blinded doses of crofelemer to support longer-term safety and efficacy for crofelemer

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failu

Thu, 10 Sep 2026 09:00:00 -0400

Continuation of treatment with blinded doses of crofelemer in the extension phase of the trial will support company's plans to file an NDA in mid-2027 for MVID, an ultrarare pediatric disease

Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

Tue, 08 Sep 2026 09:00:00 -0400

Neonorm^® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs

Jaguar expects Neonorm Dog to be available through other select online and animal health retail channels shortly, including Chewy

SAN FRANCISCO, CA / ACCESS Newswire / September 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Neonorm Dog is now available on Amazon. A new extension of Jaguar's Neonorm franchise for

Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

Tue, 08 Sep 2026 09:00:00 -0400

Jaguar expects Neonorm Dog to be available through other select online and animal health retail channels shortly, including Chewy

Jaguar Health provides crofelemer to infant for compassionate use

Fri, 04 Sep 2026 08:33:48 -0400

Jaguar Health, Inc. (NASDAQ: JAGX) announced that its subsidiary Napo Pharmaceuticals is providing crofelemer powder for oral solution to an infant patient with intestinal failure (IF) caused by congenital sodium diarrhea (CSD), the result of a mutation in the GUCY2C gene.

The treatment is being administered as adjunctive therapy to parenteral support (PS) under a compassionate use arrangement, according to a company statement. The goal is to reduce the infant's daily and weekly PS requirements, consistent with outcomes observed in other pediatric IF patients.

Jaguar said it has completed the randomized double-blind treatment phase of a pivotal clinical trial of liquid oral

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

Fri, 04 Sep 2026 08:30:00 -0400

Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including microvillus inclusion disease (MVID)

Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval

SAN FRANCISCO, CA / ACCESS Newswire / September 4, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer powder for oral solution for treatment of intestinal failure

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

Fri, 04 Sep 2026 08:30:00 -0400

Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval

Jaguar Health launches Neonorm Dog for canine digestive support

Wed, 26 Aug 2026 09:01:21 -0400

Jaguar Health, Inc. (NASDAQ: JAGX) announced the commercial launch of Neonorm Dog, a plant-based, non-prescription product intended to support normal stool consistency and gastrointestinal fluid balance in dogs.

The product extends Jaguar's existing Neonorm franchise, which currently includes Neonorm Foal and Neonorm Calf. Like those products, Neonorm Dog contains a standardized botanical extract derived from the Croton lechleri tree. The company said the product is not intended to diagnose, treat, cure, or prevent any disease, and is not a substitute for veterinary care.

Jaguar said it expects Neonorm Dog to become available through Amazon and Chewy, as well as select animal health

Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

Wed, 26 Aug 2026 09:00:00 -0400

Jaguar expects to make Neonorm Dog available through both Amazon and Chewy soon

SAN FRANCISCO, CA / ACCESS Newswire / August 26, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced the initiation of the commercial launch of Neonorm Dog, a new extension of Jaguar's Neonorm franchise for companion and production animals. Neonorm Dog is

Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs

Wed, 26 Aug 2026 09:00:00 -0400

Jaguar expects to make Neonorm Dog available through both Amazon and Chewy soon

Form 424B3 Jaguar Health, Inc.

Fri, 21 Aug 2026 15:01:00 -0400

si-local-file:///var/storage/secattach/20260821/26960962.html

Form 424B3 Jaguar Health, Inc.

Fri, 21 Aug 2026 15:01:00 -0400

si-local-file:///var/storage/secattach/20260821/26960962.html

Jaguar Health (JAGX) Tops Q2 EPS by 3647c

Wed, 19 Aug 2026 17:25:52 -0400

Jaguar Health (NASDAQ: JAGX) reported Q2 EPS of ($15.68), $36.47 better than the analyst estimate of ($52.15). Revenue for the quarter came in at $1.23 million versus the consensus estimate of $4.24 million.

For earnings history and earnings-related data on Jaguar Health (JAGX) click here.

Form 8-K Jaguar Health, Inc. For: Aug 19

Wed, 19 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260819/26950251.html

Form 8-K Jaguar Health, Inc. For: Aug 19

Wed, 19 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260819/26950251.html

Jaguar Health Reports Second Quarter 2026 Financials

Wed, 19 Aug 2026 16:00:00 -0400

Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patient with the ultrarare microvillus inclusion disease (MVID); company expects clinical package for NDA for MVID to be ready by end of 2026, allowing submission of NDA in Q2 2027

REMINDER: Jaguar to host investor webcast

Jaguar Health Reports Second Quarter 2026 Financials

Wed, 19 Aug 2026 16:00:00 -0400

Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patient with the ultrarare microvillus inclusion disease (MVID); company expects clinical package for NDA for MVID to be ready by end of 2026, allowing submission of NDA in Q2 2027
REMINDER: Jaguar to host investor webcast

Form 10-Q Jaguar Health, Inc. For: Jun 30

Wed, 19 Aug 2026 13:18:00 -0400

http://archive.fast-edgar.com/20260819/AV22M22FZZ2RPJZU22JG2ZYQI6GS4Z22Z282

Filed on: August 19, 2026

Form 10-Q Jaguar Health, Inc. For: Jun 30

Wed, 19 Aug 2026 13:18:00 -0400

http://archive.fast-edgar.com/20260819/AV22M22FZZ2RPJZU22JG2ZYQI6GS4Z22Z282

Filed on: August 19, 2026

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates

Tue, 18 Aug 2026 09:00:00 -0400

Company plans to file its Earnings Report on August 19, 2026 on Form 10-Q for the quarter ended June 30, 2026

SAN FRANCISCO, CA / ACCESS Newswire / August 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, August 19, 2026 at 4:30 p.m. Eastern to review second-quarter 2026 financials and provide corporate updates.
Participation Instructions for Jaguar Health Investor Webcast
When: Wednesday, August 19, 2026 at 4:30 p.m. Eastern
Participant Registration & Access Link: Click

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates

Tue, 18 Aug 2026 09:00:00 -0400

Company plans to file its Earnings Report on August 19, 2026 on Form 10-Q for the quarter ended June 30, 2026

SAN FRANCISCO, CA / ACCESS Newswire / August 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, August 19, 2026 at 4:30 p.m. Eastern to review second-quarter 2026 financials and provide corporate updates.
Participation Instructions for Jaguar Health Investor Webcast
When: Wednesday, August 19, 2026 at 4:30 p.m. Eastern
Participant Registration & Access Link: Click

Form EFFECT Jaguar Health, Inc.

Mon, 17 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260817/26934367.html

Form EFFECT Jaguar Health, Inc.

Mon, 17 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260817/26934367.html

Form NT 10-Q Jaguar Health, Inc. For: Jun 30

Fri, 14 Aug 2026 17:25:00 -0400
si-local-file:///var/storage/secattach/20260814/26932881.html